Rationally designed oxaliplatin-nanoparticle for enhanced antitumor efficacy

Nanotechnology

Volumn 23, Issue 7, 2012, Pages

  Paraskar, Abhimanyu ^a   Soni, Shivani ^a,d   Roy, Bhaskar ^a   Papa, Anne Laure ^a   Sengupta, Shiladitya ^a,b,c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MIT DIVISION OF HEALTH SCIENCES AND TECHNOLOGY   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d ALABAMA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI-TUMOR EFFICACY; ANTI-TUMORS; ATOMIC ABSORPTION SPECTROSCOPY; BIOACTIVATION; BIODISTRIBUTIONS; BODY WEIGHT; CANCER CHEMOTHERAPEUTICS; CANCER CHEMOTHERAPY; CYTOTOXIC; DRUG DELIVERY VEHICLES; IN-VITRO; IN-VIVO; LEAVING GROUPS; LIGHT SCATTER; MALEIC ACID COPOLYMERS; MONOMERIC UNITS; NANO SCALE; NANOMEDICINES; NEPHROTOXICITY; OXALIPLATIN; PH-DEPENDENT; PHYSICOCHEMICAL PROPERTY; POLYISOBUTYLENES; POLYMERIC NANOPARTICLES; RATIONAL DESIGN; SELF-ASSEMBLED; TUMOR ACCUMULATION; TUMOR INHIBITION;

ATOMIC SPECTROSCOPY; CHEMOTHERAPY; DISEASES; DRUG DELIVERY; INDUCTIVELY COUPLED PLASMA; NANOPARTICLES; PLATINUM; POLYMERS; TUMORS;

PLATINUM COMPOUNDS;

((1R,2R) 1,2 DIAMINOCYCLOHEXANE)PLATINUM(II); ((1R,2R)-1,2-DIAMINOCYCLOHEXANE)PLATINUM(II); ANTINEOPLASTIC AGENT; GLUCOSAMINE; MALEIC ACID; MALEIC ACID DERIVATIVE; NANOPARTICLE; OXALIPLATIN; PLATINUM COMPLEX; POLYENE; POLYISOBUTYLENE; POLYMER;

ANIMAL; ARTICLE; BREAST; BREAST TUMOR; CELL LINE; CHEMISTRY; DRUG EFFECT; FEMALE; HUMAN; MOUSE; PATHOLOGY; ULTRASTRUCTURE;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST; BREAST NEOPLASMS; CELL LINE; FEMALE; GLUCOSAMINE; HUMANS; MALEATES; MICE; NANOPARTICLES; ORGANOPLATINUM COMPOUNDS; POLYENES; POLYMERS;

EID: 84856201512     PISSN: 09574484     EISSN: 13616528     Source Type: Journal    
DOI: 10.1088/0957-4484/23/7/075103     Document Type: Article

References (36)

1. Kelland L 2007 The resurgence of platinum-based cancer chemotherapy Nature Rev. Cancer 7 57384 (Pubitemid 47106628)
2. Leong C O et al 2007 The p63/p73 network mediates chemosensitivity to cisplatin in a biologically defined subset of primary breast cancers J. Clin. Invest. 117 137080
3. Madias N E and Harrington J T 1978 Platinum nephrotoxicity Am. J. Med. 65 30714 (Pubitemid 9003377)
4. Knox R J, Friedlos F, Lydall D A and Roberts J J 1986 Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis- diamminedichloroplatinum (II) and cis-diammine-(1,1-cyclobutanedicarboxylato) platinum (II) differ only in the kinetics of their interaction with DNA Cancer Res. 46 19729 (Pubitemid 16080411)
5. Kasparov D, Vrna O, Kleinwchter V and Brabec V 1987 The effect of platinum derivatives on interfacial properties of DNA Biophys. Chem. 28 1917 (Pubitemid 18032879)
6. Rixe O, Ortuzar W, Alvarez M, Parker R, Reed E, Paull K and Fojo T 1996 Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institutes Anticancer Drug Screen panel Biochem. Pharmacol. 52 185565 (Pubitemid 26419675)
7. Raymond E, Chaney S G, Taamma A and Cvitkovic E 1998 Oxaliplatin: a review of preclinical and clinical studies Ann. Oncol. 9 105371 (Pubitemid 28518143)
8. Spingler B, Whittington D A and Lippard S J 2001 2.4 A crystal structure of an oxaliplatin 1,2-d(GpG) intrastrand cross-link in a DNA dodecamer duplex Inorg. Chem. 40 5596602 (Pubitemid 32999342)
9. Woynarowski J M, Chapman W G, Napier C, Herzig M C and Juniewicz P 1998 Sequence-and region-specificity of oxaliplatin adducts in naked and cellular DNA Mol. Pharmacol. 54 7707 (Pubitemid 28523169)
10. Woynarowski J M et al 2000 Oxaliplatin-induced damage of cellular DNA Mol. Pharmacol. 58 9207
11. Paraskar A S et al 2010 Harnessing structure-activity relationship to engineer a cisplatin nanoparticle for enhanced antitumor efficacy Proc. Natl Acad. Sci. USA 107 1243540
12. Basu S, Harfouche R, Soni S, Chimote G, Mashelkar R A and Sengupta S 2009 Nanoparticle-mediated targeting of MAPK signaling predisposes tumor to chemotherapy Proc. Natl Acad. Sci. USA 106 795761
13. Sengupta S, Tyagi P, Velpandian T, Gupta Y K and Gupta S K 2000 Etoposide encapsulated in positively charged liposomes: pharmacokinetic studies in mice and formulation stability studies Pharmacol. Res. 42 45964
14. Ferrari M 2005 Cancer nanotechnology: opportunities and challenges Nature Rev. Cancer 5 16171 (Pubitemid 40314948)
15. Moghimi S M et al 2001 Long-circulating and target-specific nanoparticles: theory to practice Pharmacol. Rev. 53 283318 (Pubitemid 32476118)
16. Yuan F, Dellian M, Fukumura D, Leunig M, Berk D A, Torchilin V P and Jain R K 1995 Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size Cancer Res. 55 37526
17. Avgoustakis K et al 2002 PLGAmPEG nanoparticles of cisplatin: in vitro nanoparticle degradation, in vitro drug release and in vivo drug residence in blood properties J. Control. Release 79 12335 (Pubitemid 34164166)
18. Fujiyama J et al 2003 Cisplatin incorporated in microspheres: development and fundamental studies for its clinical application J. Control. Release 89 397408 (Pubitemid 36555899)
19. Boulikas T, Stathopoulos G P, Volakakis N and Vougiouka M 2005 Systemic Lipoplatin infusion results in preferential tumor uptake in human studies Anticancer Res. 25 30319
20. Seetharamu N, Kim E, Hochster H, Martin F and Muggia F 2010 Phase II study of liposomal cisplatin (SPI-77) in platinum-sensitive recurrences of ovarian cancer Anticancer Res. 30 5415
21. Haxton K J and Burt H M 2009 Polymeric drug delivery of platinum-based anticancer agents J. Pharm. Sci. 98 2299316
22. Stathopoulos G P, Boulikas T, Kourvetaris A and Stathopoulos J 2006 Liposomal oxaliplatin in the treatment of advanced cancer: a phase I study Anticancer Res. 26 148993
23. Yang C, Liu H Z, Lu W D and Fu Z X 2011 PEG-liposomal oxaliplatin potentialization of antitumor efficiency in a nude mouse tumor-xenograft model of colorectal carcinoma Oncol. Rep. 25 16218
24. Gianasi E, Wasil M, Evagorou E G, Keddle A, Wilson G and Duncan R 1999 HPMA copolymer platinates as novel antitumour agents: in vitro properties, pharmacokinetics and antitumour activity in vivo Eur. J. Cancer 35 9941002 (Pubitemid 29277137)
25. Rice J R, Gerberich J L, Nowotnik D P and Howell S B 2006 Preclinical efficacy and pharmacokinetics of AP5346, a novel diaminocyclohexaneplatinum tumor-targeting drug delivery system Clin. Cancer Res. 12 224854
26. Brown S D, Nativo P, Smith J A, Stirling D, Edwards P R, Venugopal B, Flint D J, Plumb J A, Graham D and Wheate N J 2010 Gold nanoparticles for the improved anticancer drug delivery of the active component of oxaliplatin J. Am. Chem. Soc. 132 467884
27. Raymond E, Faivre S, Woynarowski J M and Chaney S G 1998 Oxaliplatin: mechanism of action and antineoplastic activity Semin. Oncol. 25 412 (Pubitemid 28248696)
28. Davies M S, Berners-Price S J and Hambley T W 2000 Slowing of cisplatin aquation in the presence of DNA but not in the presence of phosphate: improved understanding of sequence selectivity and the roles of monoaquated and diaquated species in the binding of cisplatin to DNA Inorg. Chem. 39 560313 (Pubitemid 32065704)
29. Gao W G, Pu S P, Liu W P, Liu Z D and Yang Y K 2003 The aquation of oxaliplatin and the effect of acid Yao Xue Xue Bao 38 2236
30. Powles T, Perry J and Shamash J 2007 A comparison of the platinum analogues in bladder cancer cell lines Urol. Int. 79 6772 (Pubitemid 47051822)
31. Lee K Y, Ha W S and Park W H 1995 Blood compatibility and biodegradability of partially N-acylated chitosan derivatives Biomaterials 16 12116
32. Song C W 2006 Influence of tumor pH on therapeutic response Cancer Drug Discovery and Development: Cancer Drug Resistance ed B Teicher (Totowa, NJ: Humana Press) pp 2142
33. Shen F Z, Wang J, Liang J, Mu K, Hou J Y and Wang Y T 2010 Low-dose metronomic chemotherapy with cisplatin: can it suppress angiogenesis in H22 hepatocarcinoma cells? Int. J. Exp. Pathol. 91 106
34. Choi H S, Liu W, Misra P, Tanaka E, Zimmer J P, Itty Ipe B, Bawendi M G and Frangioni J V 2007 Renal clearance of quantum dots Nature Biotechnol. 25 116570 (Pubitemid 47538116)
35. Choi C H, Zuckerman J E, Webster P and Davis M E 2011 Targeting kidney mesangium by nanoparticles of defined size Proc. Natl Acad. Sci. USA 108 665661
36. Sood P, Thurmond K B 2nd, Jacob J E, Waller L K, Silva G O, Stewart D R and Nowotnik D P 2006 Synthesis and characterization of AP5346, a novel polymer-linked diaminocyclohexyl platinum chemotherapeutic agent Bioconjug. Chem. 17 12709 (Pubitemid 44455337)